EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Y-mAbs Therapeutics, Inc. (YMAB) had EBIT Margin of -35.58% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$87.69M |
|
$-29.67M |
|
$15.00M |
|
$72.68M |
|
$118.89M |
|
$-31.20M |
|
$1.39M |
|
$-29.81M |
|
$-29.81M |
|
$-29.67M |
|
$-29.67M |
|
$-29.67M |
|
$-29.67M |
|
$-31.20M |
|
$-30.67M |
|
44.33M |
|
44.33M |
|
$-0.67 |
|
$-0.67 |
|
| Balance Sheet Financials | |
$98.51M |
|
$0.04M |
|
$21.39M |
|
$119.90M |
|
$23.70M |
|
-- |
|
$4.20M |
|
$27.90M |
|
$92.00M |
|
$89.73M |
|
$92.00M |
|
44.99M |
|
| Cash Flow Statement Financials | |
$-15.71M |
|
-- |
|
$4.31M |
|
$78.64M |
|
$67.23M |
|
$-11.40M |
|
$14.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
82.89% |
|
-35.58% |
|
|
EBIT Margin |
-35.58% |
-34.97% |
|
-34.00% |
|
-33.83% |
|
$-15.71M |
|
-- |
|
-- |
|
-- |
|
0.73 |
|
2.08 |
|
4.45 |
|
81.95 |
|
-32.24% |
|
-33.06% |
|
-24.74% |
|
-32.24% |
|
$2.05 |
|
$-0.35 |
|
$-0.35 |
|